|Day Low/High||126.06 / 134.06|
|52 Wk Low/High||110.56 / 193.45|
The Nasdaq rose 0.7% to an all-time high of 5,403. The S&P 500 was up 0.3%, and the Dow Jones Industrial Average gained 0.2%.
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that management will present at the Citi 2016 Global Healthcare Conference on Wednesday, December 7, 2016 at 11:00 a.
Here are Tuesday's top research calls, including an upgrade for Pfizer, and downgrades for Goldman Sachs, Johnson & Johnson, Delphi and Darden Restaurants.
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced today that researchers presented new data from an analysis of patients enrolled in the Global atypical Hemolytic Uremic Syndrome (aHUS) Registry, demonstrating that...
Pharma stocks have bounced back from their prior selloff, but whether they will continue their upward trend under a Donald Trump administration remains unclear.
For as much as we love and respect you, Gilead, the current situation is unacceptable. The once great and mighty biotech Gilead cannot trade at a 6x forward earnings multiple!
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that it received a notification letter on November 15, 2016 from The NASDAQ Stock Market ("NASDAQ").
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced today that researchers presented new longer-term data from an ongoing, open-label extension of the pivotal Phase 3 ARISE trial of Kanuma ® (sebelipase alfa) in...
Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Alexion Pharmaceuticals, Inc.
Levi & Korsinsky announces it has commenced an investigation of Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals disclosed Wednesday its board of directors is investigating allegations of improper sales practices tied to its top-selling drug Soliris.
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that it has filed with the U.
The biotech company cancelled its conference appearance and took its time filing its Form 10-Q with the Securities and Exchange Commission.
Jim Cramer explains the recent moves in biotechs and comments on reports regarding a Justice Department investigation into generic drug makers.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers will present new interim data from a Phase 1/2 dose-escalation study of ALXN1210, the Company's investigational, highly innovative longer-acting...
Here's a window into what institutional investors may be doing and how to profit from that.
Consider buying this biotech stock on weakness after a strong run higher Thursday.
Alexion Pharmaceuticals (ALXN) posted 2016 third-quarter results that surpassed Wall Street's expectations before today's market open.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the initiation of two Phase 3 trials of ALXN1210, a highly innovative, longer-acting anti-C5 antibody that inhibits terminal complement.
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the third quarter of 2016.